社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
aiyohyun
IP属地：海外
+关注
帖子 · 217
帖子 · 217
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
aiyohyun
aiyohyun
·
2021-10-24
Ok
US IPO Week Ahead: Semiconductors, energy storage, designer apparel, and more in a 12 IPO week<blockquote>美国IPO周：12周IPO中的半导体、储能、设计师服装等</blockquote>
The IPO market continues to stay busy with 12 IPOs schedule to raise $6.8 billion in the week ahead.
US IPO Week Ahead: Semiconductors, energy storage, designer apparel, and more in a 12 IPO week<blockquote>美国IPO周：12周IPO中的半导体、储能、设计师服装等</blockquote>
看
2,420
回复
1
点赞
8
编组 21备份 2
分享
举报
aiyohyun
aiyohyun
·
2021-10-23
Ok
非常抱歉，此主贴已删除
看
3,237
回复
1
点赞
4
编组 21备份 2
分享
举报
aiyohyun
aiyohyun
·
2021-10-22
Good
非常抱歉，此主贴已删除
看
2,289
回复
1
点赞
5
编组 21备份 2
分享
举报
aiyohyun
aiyohyun
·
2021-10-21
Ok
3 Biotech Stocks That Are Ridiculously Overpriced<blockquote>3只定价过高的生物科技股</blockquote>
Beauty is in the eye of the beholder -- and, in many cases, so is the appropriate valuation of a sto
3 Biotech Stocks That Are Ridiculously Overpriced<blockquote>3只定价过高的生物科技股</blockquote>
看
3,080
回复
1
点赞
1
编组 21备份 2
分享
举报
aiyohyun
aiyohyun
·
2021-10-20
Ok
非常抱歉，此主贴已删除
看
1,850
回复
2
点赞
8
编组 21备份 2
分享
举报
aiyohyun
aiyohyun
·
2021-10-19
Okk
Disney+ magic fades: Barclays downgrades Walt Disney after three years<blockquote>迪士尼+魔力消退：巴克莱三年后下调华特迪士尼评级</blockquote>
Walt Disney's stock received a rare Wall Street downgrade on Monday, as Barclays called for bold cha
Disney+ magic fades: Barclays downgrades Walt Disney after three years<blockquote>迪士尼+魔力消退：巴克莱三年后下调华特迪士尼评级</blockquote>
看
2,329
回复
1
点赞
7
编组 21备份 2
分享
举报
aiyohyun
aiyohyun
·
2021-10-17
Ok
非常抱歉，此主贴已删除
看
4,220
回复
1
点赞
4
编组 21备份 2
分享
举报
aiyohyun
aiyohyun
·
2021-10-15
Ok
非常抱歉，此主贴已删除
看
1,977
回复
1
点赞
7
编组 21备份 2
分享
举报
aiyohyun
aiyohyun
·
2021-10-14
Ok
Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday<blockquote>为什么NRx Pharmaceuticals股价周四再次上涨</blockquote>
New clinical trial results bode well for aviptadil in treating critically ill COVID-19 patients.
Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday<blockquote>为什么NRx Pharmaceuticals股价周四再次上涨</blockquote>
看
2,996
回复
1
点赞
1
编组 21备份 2
分享
举报
aiyohyun
aiyohyun
·
2021-10-13
Ok
非常抱歉，此主贴已删除
看
2,066
回复
1
点赞
3
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3582936698066263","uuid":"3582936698066263","gmtCreate":1619847210575,"gmtModify":1619890947066,"name":"aiyohyun","pinyin":"aiyohyun","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":18,"headSize":303,"tweetSize":217,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.06.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"海外","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":858879478,"gmtCreate":1635040396980,"gmtModify":1635040513336,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582936698066263","idStr":"3582936698066263"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/858879478","repostId":"1174514229","repostType":4,"repost":{"id":"1174514229","kind":"news","pubTimestamp":1635035471,"share":"https://www.laohu8.com/m/news/1174514229?lang=zh_CN&edition=full","pubTime":"2021-10-24 08:31","market":"us","language":"en","title":"US IPO Week Ahead: Semiconductors, energy storage, designer apparel, and more in a 12 IPO week<blockquote>美国IPO周：12周IPO中的半导体、储能、设计师服装等</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1174514229","media":"Renaissance Capital","summary":"The IPO market continues to stay busy with 12 IPOs schedule to raise $6.8 billion in the week ahead.","content":"<p>The IPO market continues to stay busy with 12 IPOs schedule to raise $6.8 billion in the week ahead.</p><p><blockquote>IPO市场继续保持繁忙，未来一周将有12起IPO计划筹集68亿美元。</blockquote></p><p> Semiconductor foundry <b>GlobalFoundries</b>(GFS) plans to raise $2.4 billion at a $24.6 billion market cap. Backed by Abu Dhabi’s Mubadala, US-based GlobalFoundries is one of the world’s leading specialty semiconductor foundries. Unprofitable with lumpy growth, the company states that it is the only scaled pure-play foundry with a global footprint that is not based in China.</p><p><blockquote>半导体代工<b>GlobalFoundries</b>(GFS)计划以246亿美元的市值筹集24亿美元。总部位于美国的GlobalFoundries得到阿布扎比穆巴达拉的支持，是全球领先的特种半导体代工厂之一。由于增长不稳定，该公司表示，它是唯一一家业务遍及全球但总部不在中国的规模化纯代工厂。</blockquote></p><p> Enterprise cloud data management platform <b>Informatica</b>(INFA) plans to raise $885 million at an $8.7 billion market cap. This company provides data integration services on its AI-powered platform to over 5,700 customers through both licenses and subscriptions. Although it will be highly leveraged post-IPO, Informatica is a recognized leader in the global data management market and saw strong subscription ARR growth in the 1H21.</p><p><blockquote>企业云数据管理平台<b>计算机科学</b>(INFA)计划以87亿美元的市值筹集8.85亿美元。该公司通过许可证和订阅在其人工智能平台上向5,700多家客户提供数据集成服务。尽管IPO后的杠杆率很高，但Informatica是全球数据管理市场公认的领导者，并在2021年上半年实现了强劲的订阅ARR增长。</blockquote></p><p> Energy storage provider <b>Fluence Energy</b>(FLNC) plans to raise $698 million at a $3.8 billion market cap. Formed by Siemens and AES, this company sells energy storage products and services to utilities, independent power producers, project developers, and commercial and industrial customers. Fast growing but unprofitable, Fluence Energy deployed 942 MW of storage products as of 6/30/21.</p><p><blockquote>储能提供商<b>注量能</b>(FLNC)计划以38亿美元的市值筹集6.98亿美元。该公司由西门子和AES组成，向公用事业公司、独立电力生产商、项目开发商以及商业和工业客户销售储能产品和服务。快速增长但无利可图，截至2011年6月30日，Fluence Energy部署了942 MW的存储产品。</blockquote></p><p> Revenue cycle management platform <b>Ensemble Health Partners</b>(ENSB) plans to raise $605 million at a $3.6 billion market cap. This platform provides revenue cycle management solutions to the healthcare industry. Profitable with accelerating growth in the 1H21, Ensemble Health has over $20 billion in annual client net patient revenue under management.</p><p><blockquote>收益周期管理平台<b>合奏健康合作伙伴</b>(ENSB)计划以36亿美元的市值筹集6.05亿美元。该平台为医疗保健行业提供收入周期管理解决方案。随着2021年上半年的加速增长，Ensemble Health管理的年度客户净患者收入超过200亿美元。</blockquote></p><p> Hiring solutions provider <b>HireRight Holdings</b>(HRT) plans to raise $500 million at a $1.8 billion market cap. This company provides background checks, verification, identification, monitoring, and drug and health screening services to over 40,000 customers. HireRight was profitable on an EBIT basis in the 1H21, though cash flow swung negative.</p><p><blockquote>招聘解决方案提供商<b>雇佣权控股公司</b>(HRT)计划以18亿美元的市值筹集5亿美元。该公司为40,000多名客户提供背景调查、验证、识别、监控以及药物和健康筛查服务。尽管现金流转为负值，但HireRight在2021年上半年的息税前利润仍实现盈利。</blockquote></p><p> Online education marketplace <b>Udemy</b>(UDMY) plans to raise $406 million at a $4.3 billion market cap. This education platform provides over 183,000 courses in 75 languages to over 44 million customers in over 180 countries. Growing but unprofitable, Udemy has registered more than 73 million users since its inception.</p><p><blockquote>在线教育市场<b>Udemy</b>(UDMY)计划以43亿美元的市值筹集4.06亿美元。该教育平台为180多个国家的4400万多名客户提供75种语言的183,000多门课程。Udemy不断增长但尚未盈利，自成立以来已注册用户超过7300万。</blockquote></p><p> Chinese drug in-licensor <b>LianBio</b>(LIAN) plans to raise $325 million at a $1.8 billion market cap. Focused on China and other Asian markets, this biopharmaceutical company develops and commercializes drugs for a variety of indications. LianBio’s pipeline currently consists of nine product candidates across five different therapeutics areas.</p><p><blockquote>中国药品许可人<b>联比奥</b>(LIAN)计划以18亿美元的市值筹集3.25亿美元。这家生物制药公司专注于中国和其他亚洲市场，开发和商业化多种适应症的药物。联生物的产品线目前包括五个不同治疗领域的九种候选产品。</blockquote></p><p> <b>Rent the Runway</b>(RENT) plans to raise $293 million at a $1.4 billion market cap. This apparel rental company originally focused on a-la-carte rentals of dresses for events, but has gradually transitioned to mostly generating revenue from monthly subscription boxes. While the company has seen active subscribers and revenue rebound in the last two quarters, it is unprofitable and leveraged post-IPO.</p><p><blockquote><b>租用跑道</b>(RENT)计划以14亿美元的市值筹集2.93亿美元。这家服装租赁公司最初专注于活动服装的点菜租赁，但已逐渐过渡到主要从每月订阅箱中创收。尽管该公司在过去两个季度的活跃订户和收入有所反弹，但IPO后仍未盈利且存在杠杆作用。</blockquote></p><p> Aesthetic medical device maker <b>Candela Medical</b>(CDLA) plans to raise $250 million at a $1.7 billion market cap. Selling products directly in 18 countries and indirectly in 66 countries, this company develops medical devices for elective aesthetic procedures. Despite being hard hit by the pandemic, Candela Medical saw strong growth and turned profitable in the 1H21.</p><p><blockquote>美容医疗器械制造商<b>坎德拉医疗</b>(CDLA)计划以17亿美元的市值筹集2.5亿美元。该公司直接在18个国家销售产品，间接在66个国家销售产品，开发用于选择性美容手术的医疗设备。尽管受到疫情的严重打击，坎德拉医疗仍实现了强劲增长，并在2021年上半年扭亏为盈。</blockquote></p><p> Fire pit brand <b>Solo Brands</b>(DTC) plans to raise $200 million at a $1.5 billion market cap. Solo Brands sells fire pits, camp stoves, and other outdoor gear through its DTC platform. Fast growing and profitable, this outdoor e-commerce has an installed base of more than 2.3 million customers.</p><p><blockquote>火坑品牌<b>索罗品牌</b>(DTC)计划以15亿美元的市值筹集2亿美元。Solo Brands通过其DTC平台销售火坑、野营炉和其他户外装备。这家户外电子商务发展迅速，利润丰厚，拥有超过230万客户。</blockquote></p><p> Body contouring provider <b>AirSculpt Technologies</b>(AIRS) plans to raise $160 million at an $886 million market cap. This company provides minimally-invasive body contouring procedures through 16 centers across 13 states in the US. AirSculpt Technologies is profitable with solid growth, and has seen an increase in same-center case volume as a result of lessening effects of COVID-19.</p><p><blockquote>塑身师<b>空气雕刻技术</b>(AIRS)计划以8.86亿美元的市值筹集1.6亿美元。该公司通过美国13个州的16个中心提供微创塑身手术。AirSculpt Technologies实现盈利并稳健增长，并且由于COVID-19影响的减轻，同中心案例数量有所增加。</blockquote></p><p> Technology firm <b>Arteris</b>(AIP) plans to raise $75 million at a $555 million market cap. This technology company develops and licenses interconnect intellectual property that manages the on-chip communications in System-on-Chip semiconductor devices. Arteris is unprofitable but saw growth accelerate in the 1H21.</p><p><blockquote>科技公司<b>动脉</b>(AIP)计划以5.55亿美元的市值筹集7500万美元。这家技术公司开发并许可互连知识产权，管理片上系统半导体器件中的片上通信。Arteris尚未盈利，但在2021年上半年增长加速。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/99c3b0173e59f4e69ff484c12bd137e7\" tg-width=\"1270\" tg-height=\"704\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/64e34b3c49a856e99ba64a2d57410844\" tg-width=\"1272\" tg-height=\"582\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Street research is expected for six companies, and lock-up periods will be expiring for up to 12 companies.</p><p><blockquote>预计将有6家公司接受街头调查，多达12家公司的禁售期将到期。</blockquote></p><p> <b>IPO Market Snapshot</b></p><p><blockquote><b>IPO市场快照</b></blockquote></p><p></p><p> The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 10/22/21, the Renaissance IPO Index was up 8.2% year-to-date, while the S&P 500 was up 21.1%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Moderna (MRNA). The Renaissance International IPO Index was down 15.8% year-to-date, while the ACWX was up 9.1%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Meituan-Dianping and SoftBank.</p><p><blockquote>文艺复兴IPO指数是新上市公司的市值加权篮子。截至10/22/21，文艺复兴IPO指数今年迄今上涨了8.2%，而标普500上涨了21.1%。Renaissance Capital的IPO ETF（纽约证券交易所股票代码：IPO）跟踪该指数，持有的顶级ETF包括Uber Technologies（UBER）和Moderna（MRNA）。Renaissance International IPO指数今年迄今下跌15.8%，而ACWX指数上涨9.1%。Renaissance Capital的国际IPO ETF（纽约证券交易所股票代码：IPOS）跟踪该指数，持有最多的ETF包括美团-W大众点评和软银。</blockquote></p><p></p>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: Semiconductors, energy storage, designer apparel, and more in a 12 IPO week<blockquote>美国IPO周：12周IPO中的半导体、储能、设计师服装等</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: Semiconductors, energy storage, designer apparel, and more in a 12 IPO week<blockquote>美国IPO周：12周IPO中的半导体、储能、设计师服装等</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Renaissance Capital</strong><span class=\"h-time small\">2021-10-24 08:31</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The IPO market continues to stay busy with 12 IPOs schedule to raise $6.8 billion in the week ahead.</p><p><blockquote>IPO市场继续保持繁忙，未来一周将有12起IPO计划筹集68亿美元。</blockquote></p><p> Semiconductor foundry <b>GlobalFoundries</b>(GFS) plans to raise $2.4 billion at a $24.6 billion market cap. Backed by Abu Dhabi’s Mubadala, US-based GlobalFoundries is one of the world’s leading specialty semiconductor foundries. Unprofitable with lumpy growth, the company states that it is the only scaled pure-play foundry with a global footprint that is not based in China.</p><p><blockquote>半导体代工<b>GlobalFoundries</b>(GFS)计划以246亿美元的市值筹集24亿美元。总部位于美国的GlobalFoundries得到阿布扎比穆巴达拉的支持，是全球领先的特种半导体代工厂之一。由于增长不稳定，该公司表示，它是唯一一家业务遍及全球但总部不在中国的规模化纯代工厂。</blockquote></p><p> Enterprise cloud data management platform <b>Informatica</b>(INFA) plans to raise $885 million at an $8.7 billion market cap. This company provides data integration services on its AI-powered platform to over 5,700 customers through both licenses and subscriptions. Although it will be highly leveraged post-IPO, Informatica is a recognized leader in the global data management market and saw strong subscription ARR growth in the 1H21.</p><p><blockquote>企业云数据管理平台<b>计算机科学</b>(INFA)计划以87亿美元的市值筹集8.85亿美元。该公司通过许可证和订阅在其人工智能平台上向5,700多家客户提供数据集成服务。尽管IPO后的杠杆率很高，但Informatica是全球数据管理市场公认的领导者，并在2021年上半年实现了强劲的订阅ARR增长。</blockquote></p><p> Energy storage provider <b>Fluence Energy</b>(FLNC) plans to raise $698 million at a $3.8 billion market cap. Formed by Siemens and AES, this company sells energy storage products and services to utilities, independent power producers, project developers, and commercial and industrial customers. Fast growing but unprofitable, Fluence Energy deployed 942 MW of storage products as of 6/30/21.</p><p><blockquote>储能提供商<b>注量能</b>(FLNC)计划以38亿美元的市值筹集6.98亿美元。该公司由西门子和AES组成，向公用事业公司、独立电力生产商、项目开发商以及商业和工业客户销售储能产品和服务。快速增长但无利可图，截至2011年6月30日，Fluence Energy部署了942 MW的存储产品。</blockquote></p><p> Revenue cycle management platform <b>Ensemble Health Partners</b>(ENSB) plans to raise $605 million at a $3.6 billion market cap. This platform provides revenue cycle management solutions to the healthcare industry. Profitable with accelerating growth in the 1H21, Ensemble Health has over $20 billion in annual client net patient revenue under management.</p><p><blockquote>收益周期管理平台<b>合奏健康合作伙伴</b>(ENSB)计划以36亿美元的市值筹集6.05亿美元。该平台为医疗保健行业提供收入周期管理解决方案。随着2021年上半年的加速增长，Ensemble Health管理的年度客户净患者收入超过200亿美元。</blockquote></p><p> Hiring solutions provider <b>HireRight Holdings</b>(HRT) plans to raise $500 million at a $1.8 billion market cap. This company provides background checks, verification, identification, monitoring, and drug and health screening services to over 40,000 customers. HireRight was profitable on an EBIT basis in the 1H21, though cash flow swung negative.</p><p><blockquote>招聘解决方案提供商<b>雇佣权控股公司</b>(HRT)计划以18亿美元的市值筹集5亿美元。该公司为40,000多名客户提供背景调查、验证、识别、监控以及药物和健康筛查服务。尽管现金流转为负值，但HireRight在2021年上半年的息税前利润仍实现盈利。</blockquote></p><p> Online education marketplace <b>Udemy</b>(UDMY) plans to raise $406 million at a $4.3 billion market cap. This education platform provides over 183,000 courses in 75 languages to over 44 million customers in over 180 countries. Growing but unprofitable, Udemy has registered more than 73 million users since its inception.</p><p><blockquote>在线教育市场<b>Udemy</b>(UDMY)计划以43亿美元的市值筹集4.06亿美元。该教育平台为180多个国家的4400万多名客户提供75种语言的183,000多门课程。Udemy不断增长但尚未盈利，自成立以来已注册用户超过7300万。</blockquote></p><p> Chinese drug in-licensor <b>LianBio</b>(LIAN) plans to raise $325 million at a $1.8 billion market cap. Focused on China and other Asian markets, this biopharmaceutical company develops and commercializes drugs for a variety of indications. LianBio’s pipeline currently consists of nine product candidates across five different therapeutics areas.</p><p><blockquote>中国药品许可人<b>联比奥</b>(LIAN)计划以18亿美元的市值筹集3.25亿美元。这家生物制药公司专注于中国和其他亚洲市场，开发和商业化多种适应症的药物。联生物的产品线目前包括五个不同治疗领域的九种候选产品。</blockquote></p><p> <b>Rent the Runway</b>(RENT) plans to raise $293 million at a $1.4 billion market cap. This apparel rental company originally focused on a-la-carte rentals of dresses for events, but has gradually transitioned to mostly generating revenue from monthly subscription boxes. While the company has seen active subscribers and revenue rebound in the last two quarters, it is unprofitable and leveraged post-IPO.</p><p><blockquote><b>租用跑道</b>(RENT)计划以14亿美元的市值筹集2.93亿美元。这家服装租赁公司最初专注于活动服装的点菜租赁，但已逐渐过渡到主要从每月订阅箱中创收。尽管该公司在过去两个季度的活跃订户和收入有所反弹，但IPO后仍未盈利且存在杠杆作用。</blockquote></p><p> Aesthetic medical device maker <b>Candela Medical</b>(CDLA) plans to raise $250 million at a $1.7 billion market cap. Selling products directly in 18 countries and indirectly in 66 countries, this company develops medical devices for elective aesthetic procedures. Despite being hard hit by the pandemic, Candela Medical saw strong growth and turned profitable in the 1H21.</p><p><blockquote>美容医疗器械制造商<b>坎德拉医疗</b>(CDLA)计划以17亿美元的市值筹集2.5亿美元。该公司直接在18个国家销售产品，间接在66个国家销售产品，开发用于选择性美容手术的医疗设备。尽管受到疫情的严重打击，坎德拉医疗仍实现了强劲增长，并在2021年上半年扭亏为盈。</blockquote></p><p> Fire pit brand <b>Solo Brands</b>(DTC) plans to raise $200 million at a $1.5 billion market cap. Solo Brands sells fire pits, camp stoves, and other outdoor gear through its DTC platform. Fast growing and profitable, this outdoor e-commerce has an installed base of more than 2.3 million customers.</p><p><blockquote>火坑品牌<b>索罗品牌</b>(DTC)计划以15亿美元的市值筹集2亿美元。Solo Brands通过其DTC平台销售火坑、野营炉和其他户外装备。这家户外电子商务发展迅速，利润丰厚，拥有超过230万客户。</blockquote></p><p> Body contouring provider <b>AirSculpt Technologies</b>(AIRS) plans to raise $160 million at an $886 million market cap. This company provides minimally-invasive body contouring procedures through 16 centers across 13 states in the US. AirSculpt Technologies is profitable with solid growth, and has seen an increase in same-center case volume as a result of lessening effects of COVID-19.</p><p><blockquote>塑身师<b>空气雕刻技术</b>(AIRS)计划以8.86亿美元的市值筹集1.6亿美元。该公司通过美国13个州的16个中心提供微创塑身手术。AirSculpt Technologies实现盈利并稳健增长，并且由于COVID-19影响的减轻，同中心案例数量有所增加。</blockquote></p><p> Technology firm <b>Arteris</b>(AIP) plans to raise $75 million at a $555 million market cap. This technology company develops and licenses interconnect intellectual property that manages the on-chip communications in System-on-Chip semiconductor devices. Arteris is unprofitable but saw growth accelerate in the 1H21.</p><p><blockquote>科技公司<b>动脉</b>(AIP)计划以5.55亿美元的市值筹集7500万美元。这家技术公司开发并许可互连知识产权，管理片上系统半导体器件中的片上通信。Arteris尚未盈利，但在2021年上半年增长加速。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/99c3b0173e59f4e69ff484c12bd137e7\" tg-width=\"1270\" tg-height=\"704\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/64e34b3c49a856e99ba64a2d57410844\" tg-width=\"1272\" tg-height=\"582\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Street research is expected for six companies, and lock-up periods will be expiring for up to 12 companies.</p><p><blockquote>预计将有6家公司接受街头调查，多达12家公司的禁售期将到期。</blockquote></p><p> <b>IPO Market Snapshot</b></p><p><blockquote><b>IPO市场快照</b></blockquote></p><p></p><p> The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 10/22/21, the Renaissance IPO Index was up 8.2% year-to-date, while the S&P 500 was up 21.1%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Moderna (MRNA). The Renaissance International IPO Index was down 15.8% year-to-date, while the ACWX was up 9.1%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Meituan-Dianping and SoftBank.</p><p><blockquote>文艺复兴IPO指数是新上市公司的市值加权篮子。截至10/22/21，文艺复兴IPO指数今年迄今上涨了8.2%，而标普500上涨了21.1%。Renaissance Capital的IPO ETF（纽约证券交易所股票代码：IPO）跟踪该指数，持有的顶级ETF包括Uber Technologies（UBER）和Moderna（MRNA）。Renaissance International IPO指数今年迄今下跌15.8%，而ACWX指数上涨9.1%。Renaissance Capital的国际IPO ETF（纽约证券交易所股票代码：IPOS）跟踪该指数，持有最多的ETF包括美团-W大众点评和软银。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/87676/US-IPO-Week-Ahead-Semiconductors-energy-storage-designer-apparel-and-more-i\">Renaissance Capital</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index","AIRS":"Airsculpt Technologies","RENT":"Rent the Runway, Inc.",".DJI":"道琼斯","AIP":"Arteris, Inc.","FLNC":"Fluence Energy, Inc.","UDMY":"Udemy, Inc.","INFA":"Informatica Inc.","GFS":"GLOBALFOUNDRIES Inc.",".IXIC":"NASDAQ Composite","HRT":"HireRight Holdings Corp."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/87676/US-IPO-Week-Ahead-Semiconductors-energy-storage-designer-apparel-and-more-i","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174514229","content_text":"The IPO market continues to stay busy with 12 IPOs schedule to raise $6.8 billion in the week ahead.\nSemiconductor foundry GlobalFoundries(GFS) plans to raise $2.4 billion at a $24.6 billion market cap. Backed by Abu Dhabi’s Mubadala, US-based GlobalFoundries is one of the world’s leading specialty semiconductor foundries. Unprofitable with lumpy growth, the company states that it is the only scaled pure-play foundry with a global footprint that is not based in China.\nEnterprise cloud data management platform Informatica(INFA) plans to raise $885 million at an $8.7 billion market cap. This company provides data integration services on its AI-powered platform to over 5,700 customers through both licenses and subscriptions. Although it will be highly leveraged post-IPO, Informatica is a recognized leader in the global data management market and saw strong subscription ARR growth in the 1H21.\nEnergy storage provider Fluence Energy(FLNC) plans to raise $698 million at a $3.8 billion market cap. Formed by Siemens and AES, this company sells energy storage products and services to utilities, independent power producers, project developers, and commercial and industrial customers. Fast growing but unprofitable, Fluence Energy deployed 942 MW of storage products as of 6/30/21.\nRevenue cycle management platform Ensemble Health Partners(ENSB) plans to raise $605 million at a $3.6 billion market cap. This platform provides revenue cycle management solutions to the healthcare industry. Profitable with accelerating growth in the 1H21, Ensemble Health has over $20 billion in annual client net patient revenue under management.\nHiring solutions provider HireRight Holdings(HRT) plans to raise $500 million at a $1.8 billion market cap. This company provides background checks, verification, identification, monitoring, and drug and health screening services to over 40,000 customers. HireRight was profitable on an EBIT basis in the 1H21, though cash flow swung negative.\nOnline education marketplace Udemy(UDMY) plans to raise $406 million at a $4.3 billion market cap. This education platform provides over 183,000 courses in 75 languages to over 44 million customers in over 180 countries. Growing but unprofitable, Udemy has registered more than 73 million users since its inception.\nChinese drug in-licensor LianBio(LIAN) plans to raise $325 million at a $1.8 billion market cap. Focused on China and other Asian markets, this biopharmaceutical company develops and commercializes drugs for a variety of indications. LianBio’s pipeline currently consists of nine product candidates across five different therapeutics areas.\nRent the Runway(RENT) plans to raise $293 million at a $1.4 billion market cap. This apparel rental company originally focused on a-la-carte rentals of dresses for events, but has gradually transitioned to mostly generating revenue from monthly subscription boxes. While the company has seen active subscribers and revenue rebound in the last two quarters, it is unprofitable and leveraged post-IPO.\nAesthetic medical device maker Candela Medical(CDLA) plans to raise $250 million at a $1.7 billion market cap. Selling products directly in 18 countries and indirectly in 66 countries, this company develops medical devices for elective aesthetic procedures. Despite being hard hit by the pandemic, Candela Medical saw strong growth and turned profitable in the 1H21.\nFire pit brand Solo Brands(DTC) plans to raise $200 million at a $1.5 billion market cap. Solo Brands sells fire pits, camp stoves, and other outdoor gear through its DTC platform. Fast growing and profitable, this outdoor e-commerce has an installed base of more than 2.3 million customers.\nBody contouring provider AirSculpt Technologies(AIRS) plans to raise $160 million at an $886 million market cap. This company provides minimally-invasive body contouring procedures through 16 centers across 13 states in the US. AirSculpt Technologies is profitable with solid growth, and has seen an increase in same-center case volume as a result of lessening effects of COVID-19.\nTechnology firm Arteris(AIP) plans to raise $75 million at a $555 million market cap. This technology company develops and licenses interconnect intellectual property that manages the on-chip communications in System-on-Chip semiconductor devices. Arteris is unprofitable but saw growth accelerate in the 1H21.\n\nStreet research is expected for six companies, and lock-up periods will be expiring for up to 12 companies.\nIPO Market Snapshot\nThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 10/22/21, the Renaissance IPO Index was up 8.2% year-to-date, while the S&P 500 was up 21.1%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Moderna (MRNA). The Renaissance International IPO Index was down 15.8% year-to-date, while the ACWX was up 9.1%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Meituan-Dianping and SoftBank.","news_type":1,"symbols_score_info":{"FLNC":0.9,"HRT":0.9,".DJI":0.9,"AIRS":0.9,".SPX":0.9,"GFS":0.9,"RENT":0.9,"LIAN":0.9,".IXIC":0.9,"AIP":0.9,"INFA":0.9,"CDLA":0.9,"UDMY":0.9,"DTC":0.9,"ENSB":0.9}},"isVote":1,"tweetType":1,"viewCount":2420,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":858029525,"gmtCreate":1634954585432,"gmtModify":1634954585819,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582936698066263","idStr":"3582936698066263"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/858029525","repostId":"1172683205","repostType":4,"isVote":1,"tweetType":1,"viewCount":3237,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":851300603,"gmtCreate":1634867328700,"gmtModify":1634867328828,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582936698066263","idStr":"3582936698066263"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/851300603","repostId":"2177462128","repostType":4,"isVote":1,"tweetType":1,"viewCount":2289,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853336505,"gmtCreate":1634773020125,"gmtModify":1634773020534,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582936698066263","idStr":"3582936698066263"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/853336505","repostId":"1151911991","repostType":4,"repost":{"id":"1151911991","kind":"news","pubTimestamp":1634728904,"share":"https://www.laohu8.com/m/news/1151911991?lang=zh_CN&edition=full","pubTime":"2021-10-20 19:21","market":"us","language":"en","title":"3 Biotech Stocks That Are Ridiculously Overpriced<blockquote>3只定价过高的生物科技股</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1151911991","media":"Motley Fool","summary":"Beauty is in the eye of the beholder -- and, in many cases, so is the appropriate valuation of a sto","content":"<p>Beauty is in the eye of the beholder -- and, in many cases, so is the appropriate valuation of a stock. One investor might view a stock as overvalued, while another investor sees it as relatively well priced.</p><p><blockquote>情人眼里出西施——在许多情况下，股票的适当估值也是如此。一位投资者可能认为一只股票被高估，而另一位投资者则认为它的定价相对合理。</blockquote></p><p> We asked three Motley Fool contributors which biotech stocks they think are ridiculously overpriced right now. Here's why they picked <b>Cassava Sciences</b>(NASDAQ:SAVA),<b>Ocugen</b>(NASDAQ:OCGN), and <b>Moderna</b>(NASDAQ:MRNA).</p><p><blockquote>我们询问了三位Motley Fool撰稿人，他们认为哪些生物技术股票目前定价过高。这就是他们选择的原因<b>木薯科学</b>（纳斯达克：萨瓦），<b>奥库根</b>（纳斯达克：OCGN），以及<b>现代</b>（纳斯达克：MRNA）。</blockquote></p><p> This biotech isn't worth the trouble</p><p><blockquote>这种生物技术不值得这么麻烦</blockquote></p><p> <b>Prosper Junior Bakiny(Cassava Sciences):</b>Investors have been flocking to this clinical-stage biotech all year long, pushing its share price up by well over 600%. It's still barely into the realm of mid-cap status, though, with a market cap of roughly $2 billion as of this writing.</p><p><blockquote><b>Prosper Junior Bakiny（木薯科学）：</b>投资者全年都在涌向这家处于临床阶段的生物技术公司，推动其股价上涨了600%以上。不过，截至撰写本文时，该公司的市值约为20亿美元，仍勉强进入中型股领域。</blockquote></p><p> Cassava Sciences is hardly worth that much, though.</p><p><blockquote>不过，木薯科学公司并不值那么多钱。</blockquote></p><p> It's is currently developing Simufilam for the treatment of Alzheimer's disease. Positive results from a pair of clinical trials -- coupled with the controversial approval of <b>Biogen</b>'s Aduhelm earlier this year -- have helped the company's stock perform as well as it has this year.</p><p><blockquote>该公司目前正在开发用于治疗阿尔茨海默病的Simufilam。两项临床试验的积极结果——加上有争议的批准<b>Biogen</b>今年早些时候的Aduhelm帮助该公司的股票表现出色。</blockquote></p><p> But there are some reasons to worry. First, many companies have tried to develop effective drugs directed at the underlying causes of Alzheimer's disease. Nearly all of them failed, even after successful phase 2 studies.</p><p><blockquote>但也有一些值得担心的理由。首先，许多公司试图开发针对阿尔茨海默病潜在原因的有效药物。即使在成功的二期研究之后，几乎所有的研究都失败了。</blockquote></p><p> Even the data from Biogen's pivotal trial for Aduhelm wasn't that convincing. That's why the Food and Drug Administration is insisting on a post-approval confirmatory study for the medicine. It could be taken off the market if it fails to prove that actually helps Alzheimer's patients.</p><p><blockquote>即使是百健(Biogen)对Aduhelm的关键试验的数据也不那么令人信服。这就是为什么食品和药物管理局坚持对该药物进行批准后验证性研究。如果它不能证明它实际上对阿尔茨海默氏症患者有帮助，它可能会被下架。</blockquote></p><p> Of course, just because others failed to develop an effective treatment for this condition doesn't mean Cassava Sciences will too. The point is, investors should view even the positive results Simufilam has produced so far with a healthy dose of skepticism.</p><p><blockquote>当然，仅仅因为其他人未能开发出针对这种情况的有效治疗方法并不意味着木薯科学公司也会这样做。关键是，即使是Simufilam迄今为止取得的积极成果，投资者也应该以适度的怀疑态度看待。</blockquote></p><p> Results from a 12-month open-label study of Simufilam weren't that impressive. Then there is the citizen petition that New York-based law firm Labaton Sucharow filed with the FDA requesting that the agency halt clinical trials featuring Simufilam. Labaton Sucharow is representing clients with short positions in the stock, so there are some financial incentives for it to target Cassava. Still, this dark cloud will continue to hover above the biotech for a while.</p><p><blockquote>一项为期12个月的Simufilam开放标签研究的结果并不那么令人印象深刻。然后是总部位于纽约的律师事务所Labaton Sucharow向FDA提交的公民请愿书，要求该机构停止以Simufilam为特色的临床试验。Labaton Sucharow代表持有股票空头头寸的客户，因此它瞄准木薯有一些财务激励。尽管如此，这片乌云仍将在生物技术上空盘旋一段时间。</blockquote></p><p> Add these to the other headwinds that Cassava Sciences could run into, including the very real possibility that Simufilam will fail miserably in its phase 3 clinical trials or that it will encounter regulatory setbacks, and this biotech stock looks far too risky to invest in, even at current levels.</p><p><blockquote>再加上Cassava Sciences可能遇到的其他阻力，包括Simufilam在3期临床试验中惨败或遭遇监管挫折的可能性非常真实，即使在目前的水平上。</blockquote></p><p> <b>Ocugen is too risky to take a chance on</b></p><p><blockquote><b>Ocugen风险太大，不能冒险</b></blockquote></p><p> <b>David Jagielski(Ocugen):</b>This company became popular among retail investors this year based on the hopes that it will be the next COVID-19 vaccine stock to make it big. There's just one problem: Ocugen's success in that regard will hinge on the approval of Covaxin, which it's co-developing with Indian biotech company Bharat Biotech.</p><p><blockquote><b>David Jagielski（Ocugen）：</b>这家公司今年受到散户投资者的欢迎，因为人们希望它将成为下一只做大的COVID-19疫苗股。只有一个问题：Ocugen在这方面的成功将取决于科瓦克辛的批准，该公司正在与印度生物技术公司Bharat Biotech共同开发该产品。</blockquote></p><p> Ocugen announced in June that it would pursue a Biologics License Application for its COVID-19 vaccine candidate in the U.S., based on a recommendation from the Food and Drug Administration. That involves a longer process than getting an Emergency Use Authorization, and implies that the agency may have been unwilling to grant emergency approval for the vaccine.</p><p><blockquote>Ocugen在6月份宣布，根据美国食品药品监督管理局的建议，它将在美国为其新冠肺炎候选疫苗申请生物制品许可证。这涉及比获得紧急使用授权更长的过程，并意味着该机构可能不愿意授予该疫苗的紧急批准。</blockquote></p><p> There was more positive news last week when India granted Emergency Use Authorization for Covaxinto be used to inoculate children ages 2 to 18. Unfortunately, that doesn't mean anything for Ocugen -- it only shares in the profits that the vaccine makes in Canada and the U.S.</p><p><blockquote>上周有更多积极消息，印度授予Covaxinto紧急使用授权，用于为2至18岁的儿童接种疫苗。不幸的是，这对Ocugen来说并不意味着什么——它只分享疫苗在加拿大和美国的利润。</blockquote></p><p> But even though that good news out of India will have no notable impact on Ocugen's business, its stock price jumped anyway, topping the $10 mark for the first time in months. The performance of the company and the stock have simply not been connected. Through the first six months of this year, Ocugen has reported <i>no revenue</i>. Yet its shares have risen by more than 350% year to date.</p><p><blockquote>但尽管来自印度的好消息不会对Ocugen的业务产生明显影响，但其股价仍大幅上涨，数月来首次突破10美元大关。公司的业绩和股票根本没有联系。今年前六个月，Ocugen报告<i>无收入</i>然而，其股价今年迄今已上涨超过350%。</blockquote></p><p> The good news is that there is still hope for the business beyond just its COVID-19 vaccine. The company is moving forward on its gene-therapy treatment, OCU400, and it plans to begin clinical studies on it later this year. However, the human trials phase of OCU400's development, even if it's ultimately successful, will take years.</p><p><blockquote>好消息是，除了COVID-19疫苗之外，该业务仍有希望。该公司正在推进其基因疗法OCU400，并计划在今年晚些时候开始临床研究。然而，OCU400开发的人体试验阶段，即使最终成功，也需要数年时间。</blockquote></p><p> Given its market cap of $1.6 billion, I think that investors are taking on a ton of risk by buying shares of Ocugen. My view is that this is akin to gambling onpenny stocks, except in those cases, at least, valuations can be incredibly low. In Ocugen's case, the stock may have limited upside.</p><p><blockquote>鉴于其16亿美元的市值，我认为投资者购买Ocugen股票是在承担很大的风险。我的观点是，这类似于押注细价股，除非在这些情况下，至少估值可能低得令人难以置信。就Ocugen而言，该股的上涨空间可能有限。</blockquote></p><p> A great company that's just too expensive</p><p><blockquote>一家伟大的公司，但价格太贵了</blockquote></p><p></p><p> <b>Keith Speights(Moderna)</b>: Most of the critiques that Prosper and David had for Cassava and Ocugen don't apply to Moderna at all. The company already has a huge blockbuster on the market with its COVID-19 vaccine. It's rolling in profits as sales for the vaccine continue to soar.</p><p><blockquote><b>基思·斯贝茨（现代）</b>：Prosper和David对Cassava和Ocugen的大多数批评根本不适用于Moderna。该公司的COVID-19疫苗已经在市场上取得了巨大的成功。随着疫苗销量持续飙升，该公司的利润不断增加。</blockquote></p><p> Moderna even has a promising pipeline. It hopes to soon advance cytomegalovirus (CMV) vaccine candidate mRNA-1647 into late-stage testing. The company is evaluating an experimental flu vaccine in early-stage testing and hopes to develop a combination COVID-19/flu vaccine. In total, the company has 17 clinical-stage programs.</p><p><blockquote>Moderna甚至有一个很有前途的管道。它希望很快将巨细胞病毒(CMV)候选疫苗mRNA-1647推进到后期测试。该公司正在早期测试中评估一种实验性流感疫苗，并希望开发一种新冠肺炎/流感联合疫苗。该公司总共有17个临床阶段项目。</blockquote></p><p> I think that Moderna's messenger RNA (mRNA) platform could produce many blockbuster vaccines and therapies over the coming decades. My view is that it's a great company. However, I also think that its shares are just too expensive now.</p><p><blockquote>我认为Moderna的信使RNA(mRNA)平台可以在未来几十年内生产出许多重磅疫苗和疗法。我的观点是这是一家伟大的公司。不过，我也认为它的股票现在太贵了。</blockquote></p><p> Some might point to Moderna's forward price-to-earnings multiple of 11.2 as evidence that I'm dead wrong about the stock being overvalued. However, the problem with this metric is that it only looks one year into the future. Moderna's CEO has predicted that the pandemic could effectively end by late 2022. If he's right, I suspect that the company's revenue and earnings could fall off significantly after that.</p><p><blockquote>有些人可能会指出Moderna 11.2的预期市盈率证明我对该股被高估的看法大错特错。然而，这个指标的问题在于它只着眼于未来一年。Moderna首席执行官预测，疫情可能会在2022年底有效结束。如果他是对的，我怀疑此后该公司的收入和盈利可能会大幅下降。</blockquote></p><p> Remember that Moderna's enormous success so far has resulted from a two-dose initial regimen of its COVID-19 vaccine. Boosters of that vaccine will only require one shot. More importantly, there's uncertainty about how frequently boosters will be needed. Governments around the world could also become more price-conscious about what they'll pay for COVID-19 vaccines in a post-pandemic environment.</p><p><blockquote>请记住，Moderna迄今为止的巨大成功归功于其COVID-19疫苗的两剂初始方案。该疫苗的加强剂只需要注射一针。更重要的是，需要助推器的频率存在不确定性。在大流行后的环境中，世界各国政府也可能对新冠肺炎疫苗的价格更加敏感。</blockquote></p><p> Perhaps things will unfold in a way that justifies Moderna's current valuation. For now, though, I think there are more outcomes that could cause this stock to fall than there are catalysts that could make it soar again.</p><p><blockquote>也许事情的发展会证明Moderna目前的估值是合理的。不过，就目前而言，我认为可能导致该股下跌的结果比可能使其再次飙升的催化剂更多。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Biotech Stocks That Are Ridiculously Overpriced<blockquote>3只定价过高的生物科技股</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Biotech Stocks That Are Ridiculously Overpriced<blockquote>3只定价过高的生物科技股</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-10-20 19:21</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Beauty is in the eye of the beholder -- and, in many cases, so is the appropriate valuation of a stock. One investor might view a stock as overvalued, while another investor sees it as relatively well priced.</p><p><blockquote>情人眼里出西施——在许多情况下，股票的适当估值也是如此。一位投资者可能认为一只股票被高估，而另一位投资者则认为它的定价相对合理。</blockquote></p><p> We asked three Motley Fool contributors which biotech stocks they think are ridiculously overpriced right now. Here's why they picked <b>Cassava Sciences</b>(NASDAQ:SAVA),<b>Ocugen</b>(NASDAQ:OCGN), and <b>Moderna</b>(NASDAQ:MRNA).</p><p><blockquote>我们询问了三位Motley Fool撰稿人，他们认为哪些生物技术股票目前定价过高。这就是他们选择的原因<b>木薯科学</b>（纳斯达克：萨瓦），<b>奥库根</b>（纳斯达克：OCGN），以及<b>现代</b>（纳斯达克：MRNA）。</blockquote></p><p> This biotech isn't worth the trouble</p><p><blockquote>这种生物技术不值得这么麻烦</blockquote></p><p> <b>Prosper Junior Bakiny(Cassava Sciences):</b>Investors have been flocking to this clinical-stage biotech all year long, pushing its share price up by well over 600%. It's still barely into the realm of mid-cap status, though, with a market cap of roughly $2 billion as of this writing.</p><p><blockquote><b>Prosper Junior Bakiny（木薯科学）：</b>投资者全年都在涌向这家处于临床阶段的生物技术公司，推动其股价上涨了600%以上。不过，截至撰写本文时，该公司的市值约为20亿美元，仍勉强进入中型股领域。</blockquote></p><p> Cassava Sciences is hardly worth that much, though.</p><p><blockquote>不过，木薯科学公司并不值那么多钱。</blockquote></p><p> It's is currently developing Simufilam for the treatment of Alzheimer's disease. Positive results from a pair of clinical trials -- coupled with the controversial approval of <b>Biogen</b>'s Aduhelm earlier this year -- have helped the company's stock perform as well as it has this year.</p><p><blockquote>该公司目前正在开发用于治疗阿尔茨海默病的Simufilam。两项临床试验的积极结果——加上有争议的批准<b>Biogen</b>今年早些时候的Aduhelm帮助该公司的股票表现出色。</blockquote></p><p> But there are some reasons to worry. First, many companies have tried to develop effective drugs directed at the underlying causes of Alzheimer's disease. Nearly all of them failed, even after successful phase 2 studies.</p><p><blockquote>但也有一些值得担心的理由。首先，许多公司试图开发针对阿尔茨海默病潜在原因的有效药物。即使在成功的二期研究之后，几乎所有的研究都失败了。</blockquote></p><p> Even the data from Biogen's pivotal trial for Aduhelm wasn't that convincing. That's why the Food and Drug Administration is insisting on a post-approval confirmatory study for the medicine. It could be taken off the market if it fails to prove that actually helps Alzheimer's patients.</p><p><blockquote>即使是百健(Biogen)对Aduhelm的关键试验的数据也不那么令人信服。这就是为什么食品和药物管理局坚持对该药物进行批准后验证性研究。如果它不能证明它实际上对阿尔茨海默氏症患者有帮助，它可能会被下架。</blockquote></p><p> Of course, just because others failed to develop an effective treatment for this condition doesn't mean Cassava Sciences will too. The point is, investors should view even the positive results Simufilam has produced so far with a healthy dose of skepticism.</p><p><blockquote>当然，仅仅因为其他人未能开发出针对这种情况的有效治疗方法并不意味着木薯科学公司也会这样做。关键是，即使是Simufilam迄今为止取得的积极成果，投资者也应该以适度的怀疑态度看待。</blockquote></p><p> Results from a 12-month open-label study of Simufilam weren't that impressive. Then there is the citizen petition that New York-based law firm Labaton Sucharow filed with the FDA requesting that the agency halt clinical trials featuring Simufilam. Labaton Sucharow is representing clients with short positions in the stock, so there are some financial incentives for it to target Cassava. Still, this dark cloud will continue to hover above the biotech for a while.</p><p><blockquote>一项为期12个月的Simufilam开放标签研究的结果并不那么令人印象深刻。然后是总部位于纽约的律师事务所Labaton Sucharow向FDA提交的公民请愿书，要求该机构停止以Simufilam为特色的临床试验。Labaton Sucharow代表持有股票空头头寸的客户，因此它瞄准木薯有一些财务激励。尽管如此，这片乌云仍将在生物技术上空盘旋一段时间。</blockquote></p><p> Add these to the other headwinds that Cassava Sciences could run into, including the very real possibility that Simufilam will fail miserably in its phase 3 clinical trials or that it will encounter regulatory setbacks, and this biotech stock looks far too risky to invest in, even at current levels.</p><p><blockquote>再加上Cassava Sciences可能遇到的其他阻力，包括Simufilam在3期临床试验中惨败或遭遇监管挫折的可能性非常真实，即使在目前的水平上。</blockquote></p><p> <b>Ocugen is too risky to take a chance on</b></p><p><blockquote><b>Ocugen风险太大，不能冒险</b></blockquote></p><p> <b>David Jagielski(Ocugen):</b>This company became popular among retail investors this year based on the hopes that it will be the next COVID-19 vaccine stock to make it big. There's just one problem: Ocugen's success in that regard will hinge on the approval of Covaxin, which it's co-developing with Indian biotech company Bharat Biotech.</p><p><blockquote><b>David Jagielski（Ocugen）：</b>这家公司今年受到散户投资者的欢迎，因为人们希望它将成为下一只做大的COVID-19疫苗股。只有一个问题：Ocugen在这方面的成功将取决于科瓦克辛的批准，该公司正在与印度生物技术公司Bharat Biotech共同开发该产品。</blockquote></p><p> Ocugen announced in June that it would pursue a Biologics License Application for its COVID-19 vaccine candidate in the U.S., based on a recommendation from the Food and Drug Administration. That involves a longer process than getting an Emergency Use Authorization, and implies that the agency may have been unwilling to grant emergency approval for the vaccine.</p><p><blockquote>Ocugen在6月份宣布，根据美国食品药品监督管理局的建议，它将在美国为其新冠肺炎候选疫苗申请生物制品许可证。这涉及比获得紧急使用授权更长的过程，并意味着该机构可能不愿意授予该疫苗的紧急批准。</blockquote></p><p> There was more positive news last week when India granted Emergency Use Authorization for Covaxinto be used to inoculate children ages 2 to 18. Unfortunately, that doesn't mean anything for Ocugen -- it only shares in the profits that the vaccine makes in Canada and the U.S.</p><p><blockquote>上周有更多积极消息，印度授予Covaxinto紧急使用授权，用于为2至18岁的儿童接种疫苗。不幸的是，这对Ocugen来说并不意味着什么——它只分享疫苗在加拿大和美国的利润。</blockquote></p><p> But even though that good news out of India will have no notable impact on Ocugen's business, its stock price jumped anyway, topping the $10 mark for the first time in months. The performance of the company and the stock have simply not been connected. Through the first six months of this year, Ocugen has reported <i>no revenue</i>. Yet its shares have risen by more than 350% year to date.</p><p><blockquote>但尽管来自印度的好消息不会对Ocugen的业务产生明显影响，但其股价仍大幅上涨，数月来首次突破10美元大关。公司的业绩和股票根本没有联系。今年前六个月，Ocugen报告<i>无收入</i>然而，其股价今年迄今已上涨超过350%。</blockquote></p><p> The good news is that there is still hope for the business beyond just its COVID-19 vaccine. The company is moving forward on its gene-therapy treatment, OCU400, and it plans to begin clinical studies on it later this year. However, the human trials phase of OCU400's development, even if it's ultimately successful, will take years.</p><p><blockquote>好消息是，除了COVID-19疫苗之外，该业务仍有希望。该公司正在推进其基因疗法OCU400，并计划在今年晚些时候开始临床研究。然而，OCU400开发的人体试验阶段，即使最终成功，也需要数年时间。</blockquote></p><p> Given its market cap of $1.6 billion, I think that investors are taking on a ton of risk by buying shares of Ocugen. My view is that this is akin to gambling onpenny stocks, except in those cases, at least, valuations can be incredibly low. In Ocugen's case, the stock may have limited upside.</p><p><blockquote>鉴于其16亿美元的市值，我认为投资者购买Ocugen股票是在承担很大的风险。我的观点是，这类似于押注细价股，除非在这些情况下，至少估值可能低得令人难以置信。就Ocugen而言，该股的上涨空间可能有限。</blockquote></p><p> A great company that's just too expensive</p><p><blockquote>一家伟大的公司，但价格太贵了</blockquote></p><p></p><p> <b>Keith Speights(Moderna)</b>: Most of the critiques that Prosper and David had for Cassava and Ocugen don't apply to Moderna at all. The company already has a huge blockbuster on the market with its COVID-19 vaccine. It's rolling in profits as sales for the vaccine continue to soar.</p><p><blockquote><b>基思·斯贝茨（现代）</b>：Prosper和David对Cassava和Ocugen的大多数批评根本不适用于Moderna。该公司的COVID-19疫苗已经在市场上取得了巨大的成功。随着疫苗销量持续飙升，该公司的利润不断增加。</blockquote></p><p> Moderna even has a promising pipeline. It hopes to soon advance cytomegalovirus (CMV) vaccine candidate mRNA-1647 into late-stage testing. The company is evaluating an experimental flu vaccine in early-stage testing and hopes to develop a combination COVID-19/flu vaccine. In total, the company has 17 clinical-stage programs.</p><p><blockquote>Moderna甚至有一个很有前途的管道。它希望很快将巨细胞病毒(CMV)候选疫苗mRNA-1647推进到后期测试。该公司正在早期测试中评估一种实验性流感疫苗，并希望开发一种新冠肺炎/流感联合疫苗。该公司总共有17个临床阶段项目。</blockquote></p><p> I think that Moderna's messenger RNA (mRNA) platform could produce many blockbuster vaccines and therapies over the coming decades. My view is that it's a great company. However, I also think that its shares are just too expensive now.</p><p><blockquote>我认为Moderna的信使RNA(mRNA)平台可以在未来几十年内生产出许多重磅疫苗和疗法。我的观点是这是一家伟大的公司。不过，我也认为它的股票现在太贵了。</blockquote></p><p> Some might point to Moderna's forward price-to-earnings multiple of 11.2 as evidence that I'm dead wrong about the stock being overvalued. However, the problem with this metric is that it only looks one year into the future. Moderna's CEO has predicted that the pandemic could effectively end by late 2022. If he's right, I suspect that the company's revenue and earnings could fall off significantly after that.</p><p><blockquote>有些人可能会指出Moderna 11.2的预期市盈率证明我对该股被高估的看法大错特错。然而，这个指标的问题在于它只着眼于未来一年。Moderna首席执行官预测，疫情可能会在2022年底有效结束。如果他是对的，我怀疑此后该公司的收入和盈利可能会大幅下降。</blockquote></p><p> Remember that Moderna's enormous success so far has resulted from a two-dose initial regimen of its COVID-19 vaccine. Boosters of that vaccine will only require one shot. More importantly, there's uncertainty about how frequently boosters will be needed. Governments around the world could also become more price-conscious about what they'll pay for COVID-19 vaccines in a post-pandemic environment.</p><p><blockquote>请记住，Moderna迄今为止的巨大成功归功于其COVID-19疫苗的两剂初始方案。该疫苗的加强剂只需要注射一针。更重要的是，需要助推器的频率存在不确定性。在大流行后的环境中，世界各国政府也可能对新冠肺炎疫苗的价格更加敏感。</blockquote></p><p> Perhaps things will unfold in a way that justifies Moderna's current valuation. For now, though, I think there are more outcomes that could cause this stock to fall than there are catalysts that could make it soar again.</p><p><blockquote>也许事情的发展会证明Moderna目前的估值是合理的。不过，就目前而言，我认为可能导致该股下跌的结果比可能使其再次飙升的催化剂更多。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/10/20/3-biotech-stocks-that-are-ridiculously-overpriced/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","MRNA":"Moderna, Inc.","SAVA":"Cassava Sciences Inc"},"source_url":"https://www.fool.com/investing/2021/10/20/3-biotech-stocks-that-are-ridiculously-overpriced/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151911991","content_text":"Beauty is in the eye of the beholder -- and, in many cases, so is the appropriate valuation of a stock. One investor might view a stock as overvalued, while another investor sees it as relatively well priced.\nWe asked three Motley Fool contributors which biotech stocks they think are ridiculously overpriced right now. Here's why they picked Cassava Sciences(NASDAQ:SAVA),Ocugen(NASDAQ:OCGN), and Moderna(NASDAQ:MRNA).\nThis biotech isn't worth the trouble\nProsper Junior Bakiny(Cassava Sciences):Investors have been flocking to this clinical-stage biotech all year long, pushing its share price up by well over 600%. It's still barely into the realm of mid-cap status, though, with a market cap of roughly $2 billion as of this writing.\nCassava Sciences is hardly worth that much, though.\nIt's is currently developing Simufilam for the treatment of Alzheimer's disease. Positive results from a pair of clinical trials -- coupled with the controversial approval of Biogen's Aduhelm earlier this year -- have helped the company's stock perform as well as it has this year.\nBut there are some reasons to worry. First, many companies have tried to develop effective drugs directed at the underlying causes of Alzheimer's disease. Nearly all of them failed, even after successful phase 2 studies.\nEven the data from Biogen's pivotal trial for Aduhelm wasn't that convincing. That's why the Food and Drug Administration is insisting on a post-approval confirmatory study for the medicine. It could be taken off the market if it fails to prove that actually helps Alzheimer's patients.\nOf course, just because others failed to develop an effective treatment for this condition doesn't mean Cassava Sciences will too. The point is, investors should view even the positive results Simufilam has produced so far with a healthy dose of skepticism.\nResults from a 12-month open-label study of Simufilam weren't that impressive. Then there is the citizen petition that New York-based law firm Labaton Sucharow filed with the FDA requesting that the agency halt clinical trials featuring Simufilam. Labaton Sucharow is representing clients with short positions in the stock, so there are some financial incentives for it to target Cassava. Still, this dark cloud will continue to hover above the biotech for a while.\nAdd these to the other headwinds that Cassava Sciences could run into, including the very real possibility that Simufilam will fail miserably in its phase 3 clinical trials or that it will encounter regulatory setbacks, and this biotech stock looks far too risky to invest in, even at current levels.\nOcugen is too risky to take a chance on\nDavid Jagielski(Ocugen):This company became popular among retail investors this year based on the hopes that it will be the next COVID-19 vaccine stock to make it big. There's just one problem: Ocugen's success in that regard will hinge on the approval of Covaxin, which it's co-developing with Indian biotech company Bharat Biotech.\nOcugen announced in June that it would pursue a Biologics License Application for its COVID-19 vaccine candidate in the U.S., based on a recommendation from the Food and Drug Administration. That involves a longer process than getting an Emergency Use Authorization, and implies that the agency may have been unwilling to grant emergency approval for the vaccine.\nThere was more positive news last week when India granted Emergency Use Authorization for Covaxinto be used to inoculate children ages 2 to 18. Unfortunately, that doesn't mean anything for Ocugen -- it only shares in the profits that the vaccine makes in Canada and the U.S.\nBut even though that good news out of India will have no notable impact on Ocugen's business, its stock price jumped anyway, topping the $10 mark for the first time in months. The performance of the company and the stock have simply not been connected. Through the first six months of this year, Ocugen has reported no revenue. Yet its shares have risen by more than 350% year to date.\nThe good news is that there is still hope for the business beyond just its COVID-19 vaccine. The company is moving forward on its gene-therapy treatment, OCU400, and it plans to begin clinical studies on it later this year. However, the human trials phase of OCU400's development, even if it's ultimately successful, will take years.\nGiven its market cap of $1.6 billion, I think that investors are taking on a ton of risk by buying shares of Ocugen. My view is that this is akin to gambling onpenny stocks, except in those cases, at least, valuations can be incredibly low. In Ocugen's case, the stock may have limited upside.\nA great company that's just too expensive\nKeith Speights(Moderna): Most of the critiques that Prosper and David had for Cassava and Ocugen don't apply to Moderna at all. The company already has a huge blockbuster on the market with its COVID-19 vaccine. It's rolling in profits as sales for the vaccine continue to soar.\nModerna even has a promising pipeline. It hopes to soon advance cytomegalovirus (CMV) vaccine candidate mRNA-1647 into late-stage testing. The company is evaluating an experimental flu vaccine in early-stage testing and hopes to develop a combination COVID-19/flu vaccine. In total, the company has 17 clinical-stage programs.\nI think that Moderna's messenger RNA (mRNA) platform could produce many blockbuster vaccines and therapies over the coming decades. My view is that it's a great company. However, I also think that its shares are just too expensive now.\nSome might point to Moderna's forward price-to-earnings multiple of 11.2 as evidence that I'm dead wrong about the stock being overvalued. However, the problem with this metric is that it only looks one year into the future. Moderna's CEO has predicted that the pandemic could effectively end by late 2022. If he's right, I suspect that the company's revenue and earnings could fall off significantly after that.\nRemember that Moderna's enormous success so far has resulted from a two-dose initial regimen of its COVID-19 vaccine. Boosters of that vaccine will only require one shot. More importantly, there's uncertainty about how frequently boosters will be needed. Governments around the world could also become more price-conscious about what they'll pay for COVID-19 vaccines in a post-pandemic environment.\nPerhaps things will unfold in a way that justifies Moderna's current valuation. For now, though, I think there are more outcomes that could cause this stock to fall than there are catalysts that could make it soar again.","news_type":1,"symbols_score_info":{"MRNA":0.9,"OCGN":0.9,"SAVA":0.9}},"isVote":1,"tweetType":1,"viewCount":3080,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859168090,"gmtCreate":1634679474039,"gmtModify":1634679474403,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582936698066263","idStr":"3582936698066263"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/859168090","repostId":"1113211293","repostType":4,"isVote":1,"tweetType":1,"viewCount":1850,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850601124,"gmtCreate":1634582595053,"gmtModify":1634582595397,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582936698066263","idStr":"3582936698066263"},"themes":[],"htmlText":"Okk","listText":"Okk","text":"Okk","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850601124","repostId":"1177726885","repostType":4,"repost":{"id":"1177726885","kind":"news","pubTimestamp":1634568658,"share":"https://www.laohu8.com/m/news/1177726885?lang=zh_CN&edition=full","pubTime":"2021-10-18 22:50","market":"us","language":"en","title":"Disney+ magic fades: Barclays downgrades Walt Disney after three years<blockquote>迪士尼+魔力消退：巴克莱三年后下调华特迪士尼评级</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1177726885","media":"Reuters","summary":"Walt Disney's stock received a rare Wall Street downgrade on Monday, as Barclays called for bold cha","content":"<p>Walt Disney's stock received a rare Wall Street downgrade on Monday, as Barclays called for bold changes from the media giant to reverse slowing growth at its Disney+ streaming service.</p><p><blockquote>华特迪士尼的股票周一受到华尔街罕见的下调，巴克莱银行呼吁这家媒体巨头做出大胆的改变，以扭转其Disney+流媒体服务增长放缓的局面。</blockquote></p><p> Disney Chief Executive Officer Bob Chapek last month hinted at a slowdown in Disney+, saying fourth-quarter global paid subscribers will grow by \"low single digit\" millions compared with a rise of 58.5 million in the previous three months.</p><p><blockquote>迪士尼首席执行官鲍勃·查佩克(Bob Chapek)上个月暗示Disney+将放缓，称第四季度全球付费用户将增长“低个位数”百万，而前三个月的增幅为5850万。</blockquote></p><p> Disney+, which has one of the richest portfolios of media content, had a blockbuster launch in 2019; it attracted new subscribers with its hit \"Star Wars\" and \"Avengers\" franchises.</p><p><blockquote>Disney+拥有最丰富的媒体内容组合之一，在2019年推出了重磅产品；它凭借热门的《星球大战》和《复仇者联盟》系列吸引了新订户。</blockquote></p><p> Rival streaming platforms such as Netflix Inc, Apple TV+ and Amazon Prime Video have had a different approach. They invested heavily on original content to draw in subscribers.</p><p><blockquote>Netflix Inc、苹果TV+和Amazon Prime Video等竞争对手流媒体平台采取了不同的方法。他们在原创内容上投入巨资以吸引订户。</blockquote></p><p> \"While the company (Disney) appears to be targeting one new piece of content a week, not every piece of content has the same franchise value or visibility,\" Barclays analyst Kannan Venkateshwar said.</p><p><blockquote>巴克莱分析师Kannan Venkateshwar表示：“虽然公司（迪士尼）的目标似乎是每周推出一条新内容，但并非每条内容都具有相同的特许经营价值或知名度。”</blockquote></p><p> Barclays also said the slowdown in Disney+ subscribers could not be solely attributed to a pull forward in additions in 2020, when streaming platforms gained popularity as people hunkering down at home sought entertainment.</p><p><blockquote>巴克莱还表示，Disney+用户数量的放缓不能仅仅归因于2020年新增用户数量的增加，当时随着人们呆在家里寻求娱乐，流媒体平台越来越受欢迎。</blockquote></p><p> To achieve its target of 230 million to 260 million Disney+ subscribers by the end of fiscal 2024, Disney will need to more than double its current pace of growth to at least the same level as Netflix, according to Barclays.</p><p><blockquote>巴克莱表示，为了实现到2024财年末Disney+用户数量达到2.3亿至2.6亿的目标，迪士尼需要将目前的增长速度提高一倍以上，至少达到与Netflix相同的水平。</blockquote></p><p> Netflix, which is due to report its quarterly results on Tuesday, had 209 million subscribers as of the quarter ended June. Disney+ had 116 million paying customers.</p><p><blockquote>Netflix将于周二公布季度业绩，截至6月的季度，该公司拥有2.09亿订阅用户。Disney+拥有1.16亿付费客户。</blockquote></p><p> Disney shares, which have not been downgraded by any brokerage so far this year, fell about 2% in early trading.</p><p><blockquote>迪士尼股价今年迄今未被任何券商下调评级，早盘下跌约2%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Disney+ magic fades: Barclays downgrades Walt Disney after three years<blockquote>迪士尼+魔力消退：巴克莱三年后下调华特迪士尼评级</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDisney+ magic fades: Barclays downgrades Walt Disney after three years<blockquote>迪士尼+魔力消退：巴克莱三年后下调华特迪士尼评级</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-10-18 22:50</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Walt Disney's stock received a rare Wall Street downgrade on Monday, as Barclays called for bold changes from the media giant to reverse slowing growth at its Disney+ streaming service.</p><p><blockquote>华特迪士尼的股票周一受到华尔街罕见的下调，巴克莱银行呼吁这家媒体巨头做出大胆的改变，以扭转其Disney+流媒体服务增长放缓的局面。</blockquote></p><p> Disney Chief Executive Officer Bob Chapek last month hinted at a slowdown in Disney+, saying fourth-quarter global paid subscribers will grow by \"low single digit\" millions compared with a rise of 58.5 million in the previous three months.</p><p><blockquote>迪士尼首席执行官鲍勃·查佩克(Bob Chapek)上个月暗示Disney+将放缓，称第四季度全球付费用户将增长“低个位数”百万，而前三个月的增幅为5850万。</blockquote></p><p> Disney+, which has one of the richest portfolios of media content, had a blockbuster launch in 2019; it attracted new subscribers with its hit \"Star Wars\" and \"Avengers\" franchises.</p><p><blockquote>Disney+拥有最丰富的媒体内容组合之一，在2019年推出了重磅产品；它凭借热门的《星球大战》和《复仇者联盟》系列吸引了新订户。</blockquote></p><p> Rival streaming platforms such as Netflix Inc, Apple TV+ and Amazon Prime Video have had a different approach. They invested heavily on original content to draw in subscribers.</p><p><blockquote>Netflix Inc、苹果TV+和Amazon Prime Video等竞争对手流媒体平台采取了不同的方法。他们在原创内容上投入巨资以吸引订户。</blockquote></p><p> \"While the company (Disney) appears to be targeting one new piece of content a week, not every piece of content has the same franchise value or visibility,\" Barclays analyst Kannan Venkateshwar said.</p><p><blockquote>巴克莱分析师Kannan Venkateshwar表示：“虽然公司（迪士尼）的目标似乎是每周推出一条新内容，但并非每条内容都具有相同的特许经营价值或知名度。”</blockquote></p><p> Barclays also said the slowdown in Disney+ subscribers could not be solely attributed to a pull forward in additions in 2020, when streaming platforms gained popularity as people hunkering down at home sought entertainment.</p><p><blockquote>巴克莱还表示，Disney+用户数量的放缓不能仅仅归因于2020年新增用户数量的增加，当时随着人们呆在家里寻求娱乐，流媒体平台越来越受欢迎。</blockquote></p><p> To achieve its target of 230 million to 260 million Disney+ subscribers by the end of fiscal 2024, Disney will need to more than double its current pace of growth to at least the same level as Netflix, according to Barclays.</p><p><blockquote>巴克莱表示，为了实现到2024财年末Disney+用户数量达到2.3亿至2.6亿的目标，迪士尼需要将目前的增长速度提高一倍以上，至少达到与Netflix相同的水平。</blockquote></p><p> Netflix, which is due to report its quarterly results on Tuesday, had 209 million subscribers as of the quarter ended June. Disney+ had 116 million paying customers.</p><p><blockquote>Netflix将于周二公布季度业绩，截至6月的季度，该公司拥有2.09亿订阅用户。Disney+拥有1.16亿付费客户。</blockquote></p><p> Disney shares, which have not been downgraded by any brokerage so far this year, fell about 2% in early trading.</p><p><blockquote>迪士尼股价今年迄今未被任何券商下调评级，早盘下跌约2%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/disney-magic-fades-barclays-downgrades-142636250.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIS":"迪士尼"},"source_url":"https://finance.yahoo.com/news/disney-magic-fades-barclays-downgrades-142636250.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177726885","content_text":"Walt Disney's stock received a rare Wall Street downgrade on Monday, as Barclays called for bold changes from the media giant to reverse slowing growth at its Disney+ streaming service.\nDisney Chief Executive Officer Bob Chapek last month hinted at a slowdown in Disney+, saying fourth-quarter global paid subscribers will grow by \"low single digit\" millions compared with a rise of 58.5 million in the previous three months.\nDisney+, which has one of the richest portfolios of media content, had a blockbuster launch in 2019; it attracted new subscribers with its hit \"Star Wars\" and \"Avengers\" franchises.\nRival streaming platforms such as Netflix Inc, Apple TV+ and Amazon Prime Video have had a different approach. They invested heavily on original content to draw in subscribers.\n\"While the company (Disney) appears to be targeting one new piece of content a week, not every piece of content has the same franchise value or visibility,\" Barclays analyst Kannan Venkateshwar said.\nBarclays also said the slowdown in Disney+ subscribers could not be solely attributed to a pull forward in additions in 2020, when streaming platforms gained popularity as people hunkering down at home sought entertainment.\nTo achieve its target of 230 million to 260 million Disney+ subscribers by the end of fiscal 2024, Disney will need to more than double its current pace of growth to at least the same level as Netflix, according to Barclays.\nNetflix, which is due to report its quarterly results on Tuesday, had 209 million subscribers as of the quarter ended June. Disney+ had 116 million paying customers.\nDisney shares, which have not been downgraded by any brokerage so far this year, fell about 2% in early trading.","news_type":1,"symbols_score_info":{"DIS":0.9}},"isVote":1,"tweetType":1,"viewCount":2329,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827250866,"gmtCreate":1634483388359,"gmtModify":1634483388808,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582936698066263","idStr":"3582936698066263"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/827250866","repostId":"2175146556","repostType":4,"isVote":1,"tweetType":1,"viewCount":4220,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":824299115,"gmtCreate":1634312513434,"gmtModify":1634312513781,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582936698066263","idStr":"3582936698066263"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/824299115","repostId":"2175117376","repostType":4,"isVote":1,"tweetType":1,"viewCount":1977,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825234430,"gmtCreate":1634226446182,"gmtModify":1634226446334,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582936698066263","idStr":"3582936698066263"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/825234430","repostId":"1151136903","repostType":4,"repost":{"id":"1151136903","kind":"news","pubTimestamp":1634225065,"share":"https://www.laohu8.com/m/news/1151136903?lang=zh_CN&edition=full","pubTime":"2021-10-14 23:24","market":"us","language":"en","title":"Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday<blockquote>为什么NRx Pharmaceuticals股价周四再次上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1151136903","media":"Motley Fool","summary":"New clinical trial results bode well for aviptadil in treating critically ill COVID-19 patients.","content":"<p><b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul> <li>An infectious-disease journal published results from a clinical trial with NRx Pharmaceuticals' lead candidate aviptadil.</li> <li>Aviptadil is in development for the treatment of respiratory failure related to severe COVID infection.</li> <li>The peer-reviewed results were positive but hardly sufficient to support a request for Emergency Use Authorization from the FDA.</li> </ul> <b>What happened</b></p><p><blockquote><ul><li>一份传染病杂志发表了NRx Pharmaceuticals的主要候选药物aviptadil的临床试验结果。</li><li>阿维他地尔正在开发中，用于治疗与严重COVID感染相关的呼吸衰竭。</li><li>同行评审结果是积极的，但不足以支持FDA的紧急使用授权请求。</li></ul><b>发生了什么</b></blockquote></p><p> Shares of <b>NRx Pharmaceuticals</b>(NASDAQ:NRXP) are rising sharply for the second time this week. On Tuesday, the stock jumped higher after the company relayed some positive regulatory developments. Today, investors are excited about clinical trial results for aviptadil, a potential new treatment for respiratory failure caused by COVID-19. The biotech stock was up 33.8% as of 10:54 a.m. EDT on Thursday.</p><p><blockquote>本公司之股份<b>NRx制药公司</b>（纳斯达克：NRXP）本周第二次大幅上涨。周二，在该公司转述了一些积极的监管进展后，该股跳涨。如今，投资者对aviptadil的临床试验结果感到兴奋，aviptadil是一种治疗COVID-19引起的呼吸衰竭的潜在新疗法。截至美国东部时间周四上午10:54，该生物科技股上涨33.8%。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> This morning, an infectious-disease journal published peer-reviewed results of an open-label trial with aviptadil and critically ill COVID patients. An impressive 81% of patients treated with aviptadil survived at least 60 days compared to just 21% of patients given standard care.</p><p><blockquote>今天早上，一份传染病杂志发表了一项针对阿维他地尔和危重COVID患者的开放标签试验的同行评审结果。令人印象深刻的是，81%接受阿维他地尔治疗的患者存活了至少60天，而接受标准治疗的患者仅存活了21%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e2822fcb875474824949ad943caf5b99\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> The number of severe COVID infections has dropped considerably since the study, but there could still be enough to drive significant sales. As a clinical-stage company without any approved drugs generating revenue, even modest sales of aviptadil could lead to market-beating gains for NRx Pharmaceuticals investors.</p><p><blockquote>自该研究以来，严重COVID感染的数量已大幅下降，但仍足以推动大幅销售。作为一家没有任何获批药物产生收入的临床阶段公司，即使aviptadil的适度销售也可能为NRx Pharmaceuticals投资者带来跑赢市场的收益。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Unfortunately, we still don't know when NRx Pharmaceuticals will get a chance to launch aviptadil. The results presented today are interesting, but there's more work to do.</p><p><blockquote>不幸的是，我们仍然不知道NRx Pharmaceuticals何时有机会推出aviptadil。今天展示的结果很有趣，但还有更多工作要做。</blockquote></p><p> Today's announcement came from an open-label trial conducted in a single hospital system without any randomization. Investigators simply treated 21 consecutive eligible patients who were admitted to a single hospital system in Houston during the summer of 2020.</p><p><blockquote>今天的公告来自一项在单一医院系统中进行的开放标签试验，没有任何随机化。研究人员简单地治疗了2020年夏天休斯顿一家医院系统收治的21名连续合格患者。</blockquote></p><p> In place of a placebo, investigators used patients with similar comorbidities admitted before and after the group who were treated with aviptadil. These results are interesting. On their own, though, they won't be sufficient to support an Emergency Use Authorization request.</p><p><blockquote>代替安慰剂，研究者使用了该组前后入院的具有类似合并症的患者，这些患者接受了阿维他地尔治疗。这些结果很有趣。然而，它们本身不足以支持紧急使用授权请求。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday<blockquote>为什么NRx Pharmaceuticals股价周四再次上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy NRx Pharmaceuticals Stock Is Jumping Again on Thursday<blockquote>为什么NRx Pharmaceuticals股价周四再次上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-10-14 23:24</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul> <li>An infectious-disease journal published results from a clinical trial with NRx Pharmaceuticals' lead candidate aviptadil.</li> <li>Aviptadil is in development for the treatment of respiratory failure related to severe COVID infection.</li> <li>The peer-reviewed results were positive but hardly sufficient to support a request for Emergency Use Authorization from the FDA.</li> </ul> <b>What happened</b></p><p><blockquote><ul><li>一份传染病杂志发表了NRx Pharmaceuticals的主要候选药物aviptadil的临床试验结果。</li><li>阿维他地尔正在开发中，用于治疗与严重COVID感染相关的呼吸衰竭。</li><li>同行评审结果是积极的，但不足以支持FDA的紧急使用授权请求。</li></ul><b>发生了什么</b></blockquote></p><p> Shares of <b>NRx Pharmaceuticals</b>(NASDAQ:NRXP) are rising sharply for the second time this week. On Tuesday, the stock jumped higher after the company relayed some positive regulatory developments. Today, investors are excited about clinical trial results for aviptadil, a potential new treatment for respiratory failure caused by COVID-19. The biotech stock was up 33.8% as of 10:54 a.m. EDT on Thursday.</p><p><blockquote>本公司之股份<b>NRx制药公司</b>（纳斯达克：NRXP）本周第二次大幅上涨。周二，在该公司转述了一些积极的监管进展后，该股跳涨。如今，投资者对aviptadil的临床试验结果感到兴奋，aviptadil是一种治疗COVID-19引起的呼吸衰竭的潜在新疗法。截至美国东部时间周四上午10:54，该生物科技股上涨33.8%。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> This morning, an infectious-disease journal published peer-reviewed results of an open-label trial with aviptadil and critically ill COVID patients. An impressive 81% of patients treated with aviptadil survived at least 60 days compared to just 21% of patients given standard care.</p><p><blockquote>今天早上，一份传染病杂志发表了一项针对阿维他地尔和危重COVID患者的开放标签试验的同行评审结果。令人印象深刻的是，81%接受阿维他地尔治疗的患者存活了至少60天，而接受标准治疗的患者仅存活了21%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e2822fcb875474824949ad943caf5b99\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> The number of severe COVID infections has dropped considerably since the study, but there could still be enough to drive significant sales. As a clinical-stage company without any approved drugs generating revenue, even modest sales of aviptadil could lead to market-beating gains for NRx Pharmaceuticals investors.</p><p><blockquote>自该研究以来，严重COVID感染的数量已大幅下降，但仍足以推动大幅销售。作为一家没有任何获批药物产生收入的临床阶段公司，即使aviptadil的适度销售也可能为NRx Pharmaceuticals投资者带来跑赢市场的收益。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Unfortunately, we still don't know when NRx Pharmaceuticals will get a chance to launch aviptadil. The results presented today are interesting, but there's more work to do.</p><p><blockquote>不幸的是，我们仍然不知道NRx Pharmaceuticals何时有机会推出aviptadil。今天展示的结果很有趣，但还有更多工作要做。</blockquote></p><p> Today's announcement came from an open-label trial conducted in a single hospital system without any randomization. Investigators simply treated 21 consecutive eligible patients who were admitted to a single hospital system in Houston during the summer of 2020.</p><p><blockquote>今天的公告来自一项在单一医院系统中进行的开放标签试验，没有任何随机化。研究人员简单地治疗了2020年夏天休斯顿一家医院系统收治的21名连续合格患者。</blockquote></p><p> In place of a placebo, investigators used patients with similar comorbidities admitted before and after the group who were treated with aviptadil. These results are interesting. On their own, though, they won't be sufficient to support an Emergency Use Authorization request.</p><p><blockquote>代替安慰剂，研究者使用了该组前后入院的具有类似合并症的患者，这些患者接受了阿维他地尔治疗。这些结果很有趣。然而，它们本身不足以支持紧急使用授权请求。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/10/14/why-nrx-pharmaceuticals-is-jumpng-again-on-thursda/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NRXP":"NRX Pharmaceuticals Inc."},"source_url":"https://www.fool.com/investing/2021/10/14/why-nrx-pharmaceuticals-is-jumpng-again-on-thursda/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151136903","content_text":"Key Points\n\nAn infectious-disease journal published results from a clinical trial with NRx Pharmaceuticals' lead candidate aviptadil.\nAviptadil is in development for the treatment of respiratory failure related to severe COVID infection.\nThe peer-reviewed results were positive but hardly sufficient to support a request for Emergency Use Authorization from the FDA.\n\nWhat happened\nShares of NRx Pharmaceuticals(NASDAQ:NRXP) are rising sharply for the second time this week. On Tuesday, the stock jumped higher after the company relayed some positive regulatory developments. Today, investors are excited about clinical trial results for aviptadil, a potential new treatment for respiratory failure caused by COVID-19. The biotech stock was up 33.8% as of 10:54 a.m. EDT on Thursday.\nSo what\nThis morning, an infectious-disease journal published peer-reviewed results of an open-label trial with aviptadil and critically ill COVID patients. An impressive 81% of patients treated with aviptadil survived at least 60 days compared to just 21% of patients given standard care.\nIMAGE SOURCE: GETTY IMAGES.\nThe number of severe COVID infections has dropped considerably since the study, but there could still be enough to drive significant sales. As a clinical-stage company without any approved drugs generating revenue, even modest sales of aviptadil could lead to market-beating gains for NRx Pharmaceuticals investors.\nNow what\nUnfortunately, we still don't know when NRx Pharmaceuticals will get a chance to launch aviptadil. The results presented today are interesting, but there's more work to do.\nToday's announcement came from an open-label trial conducted in a single hospital system without any randomization. Investigators simply treated 21 consecutive eligible patients who were admitted to a single hospital system in Houston during the summer of 2020.\nIn place of a placebo, investigators used patients with similar comorbidities admitted before and after the group who were treated with aviptadil. These results are interesting. On their own, though, they won't be sufficient to support an Emergency Use Authorization request.","news_type":1,"symbols_score_info":{"NRXP":0.9}},"isVote":1,"tweetType":1,"viewCount":2996,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":822634988,"gmtCreate":1634124599901,"gmtModify":1634124600090,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582936698066263","idStr":"3582936698066263"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/822634988","repostId":"2175152306","repostType":4,"isVote":1,"tweetType":1,"viewCount":2066,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}